Exact Sciences Corporation (EXAS)

$55.14

+2.23

(+4.21%)▲

Market is closed - opens 8 PM, 26 Nov 2024

Exact Sciences Corporation Key Statistics

Market Capitalization
$10.2B
Revenue TTM
$2.7B
EBITDA
$-11.3M
Earnings Per Share (EPS)
$-1.16
Profit Margin
-7.95%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-6.76%

Exact Sciences Corporation share price movements

  • $52.81
    $55.31
    $55.14
    downward going graph

    4.23%

    Downside

    Day's Volatility :4.52%

    Upside

    0.3%

    downward going graph
  • $40.62
    $79.62
    $55.14
    downward going graph

    26.33%

    Downside

    52 Weeks Volatility :48.98%

    Upside

    30.75%

    downward going graph

Exact Sciences Corporation Returns

PeriodExact Sciences Corporation
3 Months
-7.85%
6 Months
17.27%
1 Year
-16.23%
3 Years
-35.48%

Analyst Recommendation on Exact Sciences Corporation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Exact Sciences Corporation(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
26
Hold
3
3
3
Sell
00
00
00

Analyst Forecast on Exact Sciences Corporation

What analysts predicted

Upside of 27.21%

Current $55.14
Target $70.14

Exact Sciences Corporation Financials in INR & Dollars

FY18Y/Y Change
Revenue
454.5M
↑ 70.86%
Net Income
-175.1M
↑ 53.11%
Net Profit Margin
-38.54%
↑ 4.47%
FY19Y/Y Change
Revenue
876.3M
↑ 92.82%
Net Income
-84.0M
↓ 52.04%
Net Profit Margin
-9.59%
↑ 28.95%
FY20Y/Y Change
Revenue
1.5B
↑ 70.19%
Net Income
-848.5M
↑ 910.24%
Net Profit Margin
-56.9%
↓ 47.31%
FY21Y/Y Change
Revenue
1.8B
↑ 18.49%
Net Income
-595.6M
↓ 29.81%
Net Profit Margin
-33.71%
↑ 23.19%
FY22Y/Y Change
Revenue
2.1B
↑ 17.95%
Net Income
-623.5M
↑ 4.68%
Net Profit Margin
-29.91%
↑ 3.8%
FY23Y/Y Change
Revenue
2.5B
↑ 19.93%
Net Income
-204.1M
↓ 67.26%
Net Profit Margin
-8.17%
↑ 21.74%
Q2 FY23Q/Q Change
Revenue
622.1M
↑ 3.26%
Net Income
-81.0M
↑ 9.27%
Net Profit Margin
-13.02%
↓ 0.71%
Q3 FY23Q/Q Change
Revenue
628.3M
↑ 1.0%
Net Income
794.0K
↓ 100.98%
Net Profit Margin
0.13%
↑ 13.15%
Q4 FY23Q/Q Change
Revenue
646.9M
↑ 2.95%
Net Income
-49.8M
↓ 6367.76%
Net Profit Margin
-7.69%
↓ 7.82%
Q1 FY24Q/Q Change
Revenue
637.5M
↓ 1.45%
Net Income
-110.2M
↑ 121.49%
Net Profit Margin
-17.29%
↓ 9.6%
Q2 FY24Q/Q Change
Revenue
699.3M
↑ 9.68%
Net Income
-15.8M
↓ 85.66%
Net Profit Margin
-2.26%
↑ 15.03%
Q3 FY24Q/Q Change
Revenue
708.7M
↑ 1.34%
Net Income
-38.2M
↑ 141.88%
Net Profit Margin
-5.4%
↓ 3.14%
FY18Y/Y Change
Total Assets
1.5B
↑ 154.61%
Total Liabilities
843.1M
↑ 978.91%
FY19Y/Y Change
Total Assets
3.5B
↑ 130.03%
Total Liabilities
1.2B
↑ 44.44%
FY20Y/Y Change
Total Assets
4.9B
↑ 40.49%
Total Liabilities
2.1B
↑ 72.59%
FY21Y/Y Change
Total Assets
6.7B
↑ 35.73%
Total Liabilities
3.3B
↑ 56.89%
FY22Y/Y Change
Total Assets
6.2B
↓ 6.85%
Total Liabilities
3.2B
↓ 3.44%
FY23Y/Y Change
Total Assets
6.5B
↑ 3.93%
Total Liabilities
3.3B
↑ 4.47%
Q2 FY23Q/Q Change
Total Assets
6.4B
↑ 0.81%
Total Liabilities
3.3B
↑ 1.61%
Q3 FY23Q/Q Change
Total Assets
6.4B
↑ 1.03%
Total Liabilities
3.3B
↑ 0.02%
Q4 FY23Q/Q Change
Total Assets
6.5B
↑ 0.79%
Total Liabilities
3.3B
↑ 0.8%
Q1 FY24Q/Q Change
Total Assets
6.4B
↓ 1.47%
Total Liabilities
3.2B
↓ 2.48%
Q2 FY24Q/Q Change
Total Assets
6.7B
↑ 4.66%
Total Liabilities
3.5B
↑ 7.31%
Q3 FY24Q/Q Change
Total Assets
6.7B
↑ 1.13%
Total Liabilities
3.5B
↑ 1.64%
FY18Y/Y Change
Operating Cash Flow
-69.3M
↓ 3.34%
Investing Cash Flow
-781.9M
↑ 386.25%
Financing Cash Flow
934.1M
↑ 257.97%
FY19Y/Y Change
Operating Cash Flow
-115.0M
↑ 65.9%
Investing Cash Flow
-121.1M
↓ 84.52%
Financing Cash Flow
253.2M
↓ 72.9%
FY20Y/Y Change
Operating Cash Flow
136.5M
↓ 218.67%
Investing Cash Flow
-702.0M
↑ 479.85%
Financing Cash Flow
1.9B
↑ 642.4%
FY21Y/Y Change
Operating Cash Flow
-102.2M
↓ 174.91%
Investing Cash Flow
-1.1B
↑ 54.14%
Financing Cash Flow
8.5M
↓ 99.55%
FY22Y/Y Change
Operating Cash Flow
-223.6M
↑ 118.67%
Investing Cash Flow
74.1M
↓ 106.84%
Financing Cash Flow
76.5M
↑ 802.8%
Q2 FY23Q/Q Change
Operating Cash Flow
100.4M
↓ 362.79%
Investing Cash Flow
66.5M
↓ 19.85%
Financing Cash Flow
16.0M
↓ 87.99%

Exact Sciences Corporation Technicals Summary

Sell

Neutral

Buy

Exact Sciences Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Exact Sciences Corporation Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exact Sciences Corporation
Exact Sciences Corporation
-20.49%
17.27%
-16.23%
-35.48%
-32.21%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.64%
-15.2%
-10.64%
-29.45%
69.5%
Agilent Technologies Inc.
Agilent Technologies Inc.
2.24%
-9.26%
7.58%
-11.56%
66.14%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-6.94%
-10.19%
4.91%
-19.5%
64.05%
Danaher Corp.
Danaher Corp.
-2.64%
-8.13%
8.04%
-26.63%
62.82%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-6.21%
-10.01%
-3.18%
-22.15%
37.89%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exact Sciences Corporation
Exact Sciences Corporation
NA
NA
-1.07
-0.56
-0.07
-0.02
NA
17.35
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
40.31
40.31
4.39
10.73
0.59
0.23
NA
19.72
Agilent Technologies Inc.
Agilent Technologies Inc.
27.88
27.88
3.8
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
32.16
32.16
1.96
21.69
0.13
0.05
0.0
128.08
Danaher Corp.
Danaher Corp.
44.41
44.41
3.15
7.5
0.08
0.04
0.0
71.03
Iqvia Holdings Inc.
Iqvia Holdings Inc.
26.81
26.81
1.05
11.14
0.22
0.05
NA
38.37
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exact Sciences Corporation
Exact Sciences Corporation
Buy
$10.2B
-32.21%
NA
-7.95%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$34.2B
69.5%
40.31
22.53%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.5B
66.14%
27.88
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$196.3B
64.05%
32.16
14.48%
Danaher Corp.
Danaher Corp.
Buy
$170.3B
62.82%
44.41
16.39%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$37.0B
37.89%
26.81
9.17%

Exact Sciences Corporation Institutional Holdings

  • FMR Inc

    11.70%

  • Vanguard Group Inc

    9.60%

  • Capital World Investors

    8.56%

  • Wellington Management Company LLP

    7.99%

  • BlackRock Inc

    6.52%

  • State Street Corp

    4.44%

Corporate Announcements

  • Exact Sciences Corporation Earnings

    Exact Sciences Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information about Exact Sciences Corporation

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Organization
Exact Sciences Corporation
Employees
6500
CEO
Mr. Kevin T. Conroy J.D.
Industry
Health Technology

FAQs